J&J Files Lawsuit in U.S. to Block Remicade Biosim

May 21, 2017


A division of Johnson & Johnson filed a lawsuit in the U.S. District Court of New Jersey to block a copy of its rheumatoid arthritis drug, Remicade, manufactured by Samsung Bioepis Co., according to a Reuters article.

Janssen Biotech Inc. is requesting a preliminary or permanent injunction to block South Korea's Samsung Bioepis' from selling its biosimilar of Remicade and says the company violated three of its patents.

"We have filed a lawsuit against Samsung to investigate whether their biosimilar infliximab infringes on our manufacturing process patents for Remicade," Janssen told Reuters in a statement.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments